Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients
Recruiting
N/A
Interventional Study
Leprosy
Mycobacterium Leprae Infection
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 5 – 60
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 50 (estimated)
- Sponsor
- South Valley University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Mycobacterium leprae is a slow-growing bacillus that causes leprosy. the infection may take two to ten years to incubate. While the exact mechanism of infection transmission is unknown, direct bacillus absorption through the nasal or respiratory mucosa and aerosolized nasal secretions are the most common theories. The bacteria is subsequently transported by the bloodstream to the peripheral nerves…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients of both sexes with positive slit skin smear for m.leprae .
Exclusion Criteria:
* Contraindications to Multi drug therapy :
* Patients with hypersensitivity to sulfa .
* Patients with hypersensitivity to clofazimine or rifampcin.
* pregnant or lactating women.
Contacts